Showing 17,561 - 17,580 results of 21,342 for search '(( significance ((level decrease) OR (teer decrease)) ) OR ( significant decrease decrease ))', query time: 0.71s Refine Results
  1. 17561

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  2. 17562

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  3. 17563

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  4. 17564

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  5. 17565

    Rht1 functions in cell cycle progression and modulates fluconazole susceptibility. by Ci Fu (148006)

    Published 2025
    “…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …”
  6. 17566

    Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

    Published 2025
    “…(L) Fraction of glomeruli with significant changes with cued-odor. Yellow: increased, dark grey: decreased, light grey: unchanged. …”
  7. 17567

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  8. 17568

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  9. 17569

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  10. 17570

    Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma by Marianna Carrabotta (8193039)

    Published 2025
    “…<b>A,</b> Inhibition of PDX-CDS #4-C tumor growth after treatments with trabectedin and/or NVP-BEZ235. Significant reduction in tumor growth was observed after single treatments (*, <i>P</i> < 0.05, Student <i>t</i> test) but the inhibition increased after combination of the two drugs (significance was at least ***, <i>P</i> < 0.001, Student <i>t</i> test starting from day 23) or to single treatments (*, <i>P</i> < 0.05). …”
  11. 17571

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  12. 17572

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  13. 17573

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  14. 17574

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  15. 17575

    Table 1_Danggui Buxue Decoction attenuates 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone—induced lung cancer growth in A/J mice by suppressing HIF-1α/VEGF-mediated angiogenesis.do... by Wu Chen (569414)

    Published 2025
    “…By week 20, progressive multifocal opacities emerged alongside reduced pulmonary artery flow, impaired lung function, elevated TNF-α/VEGF, and decreased WBC, lymphocytes, and platelets. Compared to untreated controls, 10-week DBD treatment significantly suppressed lung tumor growth, reduced lesion microvessel density, downregulated HIF-1α and VEGF expression, and ameliorated hematological dysregulation.…”
  16. 17576

    Data Sheet 1_Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma.docx by Abraham Alí-Munive (21347201)

    Published 2025
    “…FEV<sub>1</sub>pp showed higher but not significant values from the 2–4-month period, with a median change of 12.5% (IQR: 0.3, 21.5). …”
  17. 17577
  18. 17578

    Data Sheet 1_Soil fungal community and co-occurrence network patterns at different successional stages of black locust coppice stands.docx by Huimei Tian (499744)

    Published 2025
    “…Significant changes in the relative abundance of certain fungal guilds were observed by both stand conversion and seasonal variation (p < 0.05). …”
  19. 17579

    Figure 3 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation by Anna Rutkowska (19676837)

    Published 2025
    “…Niraparib decreases CYP51A1 (lanosterol 14α-demethylase) enzyme levels (Supplementary Fig. …”
  20. 17580

    Data Sheet 1_Impact of fatigue in Crohn's disease is negatively related to resting state functional connectivity between the superior parietal lobule and parahippocampal gyrus/hipp... by Theresa A. McIver (21178337)

    Published 2025
    “…</p>Discussion<p>In people with Crohn's disease, fatigue increases as functional connectivity between brain regions involved in sensorimotor integration and memory processing decreases.</p>…”